High doses of erythropoiesis-stimulating agents were associated with an increased risk for cancer in patients on dialysis, but the real risk attributed to these medications remains unclear.

Anemia occurs frequently in patients with cancer, with estimates reaching as high as 90% in those with solid tumors. The red blood cell disorder, which may develop because of tumor-related features or ...

Investigating the role of LRP1B in chemo-resistance in advanced triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

BOSTON, Feb 22 (Reuters) - Amgen Inc. said on Thursday its anemia drug Aranesp has been removed from a list used by insurance companies to determine whether a drug should be reimbursed for a condition ...

BOSTON (Reuters) - Amgen Inc., the world's biggest biotechnology company struggling with safety concerns over its best-selling drug, is facing one of the most critical junctures in its history. Sign ...